Eli Lilly's Weight Loss Pill Foundayo and Onswik

On October 20, 2026, Eli Lilly shares climbed to a new all-time high of $1,311.75, driving the pharmaceutical giant's market capitalization to $1.17 trillion.

Bank of America projects continued market share gains over the next 12 months for Lilly's oral glucagon-like peptide-1 (GLP-1) weight-loss treatment, Foundayo, following a recommendation for approval from European regulators.

Lilly agreed to pay Metis TechBio up to $1.1 billion for artificial intelligence-enabled drug-delivery technology to expand its product pipeline beyond current diabetes and obesity medicines.

The company's Omvoh treatment met its primary endpoint in a Phase 3 pediatric ulcerative-colitis study, with 50% of induction responders achieving clinical remission at one year, prompting plans for a regulatory label expansion.

A Pennsylvania lawsuit alleges that Eli Lilly and other manufacturers inflated insulin prices by more than 1,000%, creating potential legal costs and regulatory scrutiny though no liability has been established.

For the quarter ending August 5, 2026, Eli Lilly reported earnings per share of $8.38—beating the consensus estimate of $6.40 by $1.98—alongside revenue of $22.97 billion, which exceeded the expected $20.82 billion.

Quarterly revenue surged 47.7% compared to the same period last year, supported by strong sales from its current weight-loss medications which generated approximately $14 billion.

Eli Lilly set its full-year fiscal 2026 guidance at $35.50 to $36.50 in earnings per share, while the stock trades at a price-to-earnings ratio of approximately 38 to 39.

Clinical pipeline updates showed that the oral GLP-1 (glucagon-like peptide-1, a type of medication used to treat type 2 diabetes and obesity) candidate Foundayo demonstrated greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes.

Corporate insiders sold a total of 13,500 shares worth $15,958,170 over a ninety-day period under pre-arranged Rule 10b5-1 trading plans.

Eli Lilly ($LLY) shares rose 2.5% to $1,186.95 on Wednesday following strong investor preference for defensive healthcare stocks.

The FDA expanded the approval of Jaypirca (pirtobrutinib) for the first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma without a 17p deletion, broadening the company's oncology market.

Early trial data for the company's oral glucagon-like peptide-1 receptor agonist candidate, Foundayo, showed greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes.

Institutional investors and hedge funds own 82.53% of the company's stock, with Canandaigua National Trust Co of Florida acquiring a new position valued at $19,155,000.

Eli Lilly's indirect analysis shows Foundayo 17.2 mg achieves up to 2% greater weight loss and 0.3% better A1C reduction than Novo Nordisk's 25 mg oral semaglutide in type 2 diabetes patients.

Lilly also reported that its injectable Zepbound at 15 mg produces approximately 5% more weight loss than Novo's high-dose Wegovy over a 72-week period.

Novo Nordisk contested the findings, noting the diabetes-focused study population typically experiences less weight loss than patients treated specifically for obesity.

The FDA is expected to decide on the approval of Novo's 25 mg oral semaglutide for type 2 diabetes by the end of 2026.

Eli Lilly captures approximately 70% of new senior patients following Medicare coverage expansion, while its oral obesity drug Foundayo accounts for one-third of new oral GLP-1 prescriptions.

The company broke ground on a $6.5 billion manufacturing facility in Houston to increase supply capacity for obesity medicines, with completion expected by 2030.

The FDA approved Onswik, a once-weekly insulin injection for type 2 diabetes, following successful Phase 3 trials involving over 3,400 patients.

Shares face volatility as investors weigh high valuation multiples against emerging competition from Viking Therapeutics and Novo Nordisk, whose late-stage drug candidates show potential for less frequent dosing.

The FDA approved Onswik, a once-weekly basal insulin injection for adults with type 2 diabetes, which is expected to reduce the burden of daily injections by over 300 shots per year.

Eli Lilly shares rose 3.56% to $1,191.92 following the announcement, as the drug adds a new competitive product to the company's diabetes portfolio against rival Novo Nordisk.

Approval was based on the Phase 3 QWINT clinical trials involving 3,400 adults, which demonstrated that Onswik achieved non-inferior blood sugar control compared to standard daily insulin options.

Onswik is contraindicated for patients with type 1 diabetes due to an increased risk of severe hypoglycemia, or dangerously low blood sugar levels.

The medication will be available in the U.S. in the coming months via a pre-filled KwikPen system in two concentrations: 500 units per milliliter and 1,000 units per milliliter.

Eli Lilly began construction on a 236-acre facility in Houston, Texas, designed to produce active pharmaceutical ingredients for its oral weight-loss drug, Foundayo, with full operations expected by 2030.

The project is part of a $50 billion domestic manufacturing expansion and will create 4,000 construction jobs followed by 615 permanent high-wage roles in engineering and laboratory science.

Lilly committed $15 million to San Jacinto College, including $12.5 million for workforce training in chemical synthesis and $2.5 million in scholarships to build a local talent pipeline.

Foundayo, a once-daily oral tablet approved in April 2026, generated $98 million in revenue during its first quarter on the market and currently accounts for one-third of new GLP-1 pill prescriptions.

Dozens of patients have filed lawsuits against Novo Nordisk and Eli Lilly, alleging the companies failed to warn users about a potential risk of nonarteritic anterior ischemic optic neuropathy (NAION), a condition causing sudden, permanent vision loss.

While the U.S. Food and Drug Administration is currently investigating a potential safety signal, it does not mandate warning labels for NAION, unlike regulators in Australia and the European Union.

One study of 159,000 participants with type 2 diabetes found 35 cases of NAION among GLP-1 users compared to 19 in a control group, though experts note that underlying conditions like diabetes and high blood pressure independently increase the risk of the condition.

Novo Nordisk and Eli Lilly are defending against the litigation, maintaining that patient safety is their priority and that they continue to monitor and report safety data to regulators.

Since the July launch of the Medicare Bridge program, 700,000 seniors have initiated GLP-1 weight-loss treatments, with Eli Lilly securing 70% of these new patients.

The Bridge program provides eligible Medicare Part D beneficiaries access to Zepbound, Foundayo, and Wegovy for a $50 monthly co-pay, with manufacturers supplying the drugs at a net price of $245 per month.

Lilly's injectable Zepbound remains the primary choice for patients with higher body weight and medical complications, while the oral pill Foundayo accounts for one-third of new oral GLP-1 prescriptions.

The temporary federal coverage program is scheduled to remain in effect through December 2027.

Eli Lilly's Foundayo pill now accounts for one in three new U.S. patient starts for oral GLP-1 weight-loss treatments, with market share increasing weekly since its April launch.

The company broke ground on a $6.5 billion manufacturing facility in Houston, Texas, which is scheduled to become operational by 2030 to support production of Foundayo and other small-molecule medicines.

Foundayo generated $98 million in revenue during its first full quarter on the market, with further growth expected following the July start of Medicare coverage for obesity drugs.

Eli Lilly has committed over $50 billion to manufacturing network expansion since 2020 to compete with rival Novo Nordisk, including a $27 billion investment pledged in early 2025.

Citadel acquired 704,000 additional shares of Eli Lilly during the second quarter of 2026, nearly quadrupling its position to 945,000 shares valued at $1.18 billion, making it the hedge fund's sixth-largest equity holding.

Eli Lilly launched Foundayo, its oral GLP-1 weight-loss medication, in the United Kingdom on August 24, 2026, marking the first European market availability for the drug.

Private market pricing for Foundayo in the UK ranges from £100 to £120 per month, significantly lower than the £330 monthly cost for the company's injectable Mounjaro treatment.

Wall Street analysts maintain a Strong Buy consensus on Eli Lilly with a mean price target of $1,375.78, based on 18 Buy and two Hold ratings issued within the last three months.

Eli Lilly has launched its once-daily oral weight loss and diabetes medication, Foundayo, in UK pharmacies, making the UK the first European country to authorize the drug.

The drug is licensed for individuals with a body mass index of 30 or higher, or those with a body mass index of 27 to 30 who have at least one weight-related health condition.

Foundayo is currently available only via private prescription, with monthly costs ranging from £64 for the 0.8mg entry dose to £169 for the 17.2mg maximum dose.

Unlike competing injectable treatments or other oral options, Foundayo has no specific timing, food, or water restrictions, which the company expects will improve patient adherence to the treatment regimen.

Eli Lilly is currently in discussions with the National Institute for Health and Care Excellence regarding a potential future rollout of the medication through the National Health Service.

Eli Lilly reported Q2 revenue of $22.97 billion, a 47.7% year-over-year increase, and adjusted earnings per share of $8.38, surpassing the consensus estimate of $6.40.

The U.K. Medicines and Healthcare products Regulatory Agency approved Foundayo, an oral weight-loss pill, marking the company's first European authorization for an obesity treatment.

Management reiterated fiscal 2026 earnings guidance of $35.50 to $36.50 per share, supported by strong demand for GLP-1 (glucagon-like peptide-1) medications including Mounjaro and Zepbound.

Company insiders, including EVP Anat Hakim and CAO Donald Zakrowski, sold a combined 13,500 shares over the last three months under pre-arranged Rule 10b5-1 trading plans.

The National Institute for Health and Care Excellence issued final draft guidance recommending Onswik, a once-weekly insulin injection by Eli Lilly, as an effective alternative to daily insulin treatments for type 2 diabetes patients.

The treatment reduces the annual injection burden by approximately 86%, shifting the requirement from 365 daily doses to 52 weekly administrations, which is expected to improve quality of life for patients requiring caregiver assistance.

Clinical trials indicate that the weekly injection provides blood glucose control comparable to existing long-acting treatments like insulin degludec and insulin glargine.

Finalization of the guidance is expected by September 10, 2026, pending an appeal period, though the drug must still receive a formal license from the Medicines and Healthcare products Regulatory Agency before NHS availability.